

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



丽珠医药
LIVZON

麗珠醫藥集團股份有限公司

LIVZON PHARMACEUTICAL GROUP INC.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1513)

INSIDE INFORMATION

PROPOSED SPIN-OFF AND SEPARATE LISTING OF LIVZON DIAGNOSTICS

This announcement is published by 麗珠醫藥集團股份有限公司 Livzon Pharmaceutical Group Inc.* (the “**Company**”, together with its subsidiaries, the “**Group**”), pursuant to Rule 13.09(2) of the Rules (the “**Hong Kong Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Hong Kong Stock Exchange**”) and the Inside Information Provisions (as defined in the provision of Hong Kong Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcement of the Company dated 10 November 2023 on the Proposed Spin-off and Separate Listing of Livzon Diagnostics (the “**Announcement**”). Unless otherwise specified, capitalised terms used herein shall have the same meaning as those defined in the Announcement.

The Board is pleased to announce that an application for the Proposed Spin-off and Separate Listing of Livzon Diagnostics under Practice Note 15 to the Hong Kong Listing Rules has been made by the Company to the Hong Kong Stock Exchange on 13 November 2023. Further announcement(s) will be made by the Company in due course for compliance with the Hong Kong Listing Rules.

Shareholders and potential investors should note that the Proposed Spin-off and Separate Listing is subject to, among others, approvals from the shareholders of the Company, the directors and shareholders of Livzon Diagnostics, the relevant regulatory authorities (including the CSRC, the NEEQ, the relevant stock exchange(s) in the PRC, and the Hong Kong Stock Exchange); as well as the then market conditions. There is no assurance that the Proposed Spin-off and Separate Listing will proceed or as to when it may take place. Shareholders and potential investors are reminded to exercise caution when dealing in the securities of the Company.

By order of the Board
麗珠醫藥集團股份有限公司
Livzon Pharmaceutical Group Inc. *
Yang Liang
Company Secretary

Zhuhai, China

13 November 2023

As at the date of this announcement, the Executive Directors of the Company are Mr. Tang Yanggang (President) and Mr. Xu Guoxiang (Vice Chairman and Vice President); the Non-Executive Directors of the Company are Mr. Zhu Baoguo (Chairman), Mr. Tao Desheng (Vice Chairman), Mr. Qiu Qingfeng and Mr. Yu Xiong; and the Independent Non-Executive Directors of the Company are Mr. Bai Hua, Mr. Tian Qiusheng, Mr. Wong Kam Wa, Mr. Luo Huiyuan and Ms. Cui Lijie.

** For identification purpose only*